Alembic Pharma clears USFDA inspection at Bioequivalence facility in Vadodara

New Delhi: Drug firm, Alembic Pharmaceutical's bioequivalence facilities located at Vadodara have been successfully inspected by the US Food & Drug Administration (USFDA).

"The inspection for Bioequivalence Bioanalytical and Bioequivalence Clinical were conducted by the US health regulator between 12 August 2019 to 16 August 2019 and between 12 August 2019 to 20 August 2019," Alembic Pharma said.

There were no 483s issued by USFDA at the end of the inspection, the company added.

Also Read: Alembic Pharma clears USFDA inspection at oncology unit in Panelav

Alembic Pharma, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA.

Read Also: Alembic Pharma gets USFDA nod to Teriflunomide tablets, Tobramycin ophthalmic solution